Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "Vice-President"

904 News Found

Parexel appoints Peyton Howell and Amy McKee
People | September 16, 2022

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers


Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


AstraZeneca launches up-skilling program iPHARMACY
News | September 15, 2022

AstraZeneca launches up-skilling program iPHARMACY

The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala


Lonza appoints Daniel Palmacci as President of the Cell & Gene Division
People | September 13, 2022

Lonza appoints Daniel Palmacci as President of the Cell & Gene Division

He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Diagnostic Center | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Diagnostic Center | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Diagnostic Center | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Diagnostic Center | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Evonik appoints Dr. Gaetano Blanda as Head of Animal Nutrition Business Line
People | September 08, 2022

Evonik appoints Dr. Gaetano Blanda as Head of Animal Nutrition Business Line

Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach